education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Colsancetine
Colsancetine
chloramphenicol
Manufacturer:
Sanbe
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Chloramphenicol Na succinate
Indications/Uses
Typhoid & paratyphoid fever. Infections by
Salmonella
sp,
H. influenzae
, rickettsiae, lymphogranuloma-psittacosis group & gm -ve bacteria causing bacteraemia & meningitis.
Dosage/Direction for Use
Adult, childn & infant >2 wk
50 mg/kg daily.
Newborn infant & infant/childn w/ immature metabolic processes
25 mg/kg daily. To be given in 4 doses at 6 hrly intervals.
Contraindications
Hypersensitivity. Anaemia.
Special Precautions
Prolonged treatment. Blood studies should be done. Renal or hepatic impairment. Pregnancy & lactation. Infant.
Adverse Reactions
Bone marrow depression, aplastic anaemia, Gray syndrome in infants, GI distress, hypersensitivity reaction.
View
ADR Reporting Link
Drug Interactions
Dicumarol, phenytoin, tolbutamide, fenobarb.
MIMS Class
Chloramphenicols
ATC Classification
J01BA01 - chloramphenicol ; Belongs to the class of amphenicols. Used in the systemic treatment of infections.
Regulatory Classification
K
Presentation/Packing
Form
Colsancetine powd for inj 1 g
Packing/Price
(vial) 10 × 1's (Rp169,000/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk